This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1990 Mar;42(1):1-28.

Human recombinant interleukin-2 as an experimental therapeutic

J L Winkelhake¹, S S Gauny

Affiliations

PMID: 2196590

Review

Human recombinant interleukin-2 as an experimental therapeutic

J L Winkelhake et al. Pharmacol Rev. 1990 Mar.

. 1990 Mar;42(1):1-28.

Authors

J L Winkelhake¹, S S Gauny

Affiliation

¹ Department of Pharmacology, Cetus Corporation, Emeryville, California 94608.

PMID: 2196590

No abstract available

PubMed Disclaimer

Similar articles

Rationale and therapeutic basis for patients receiving recombinant interleukin-2.
Dudjak LA. Dudjak LA. Semin Oncol Nurs. 1993 Aug;9(3 Suppl 1):3-7. Semin Oncol Nurs. 1993. PMID: 8210792 Review. No abstract available.
[Pharmacologic studies with recombinant human interleukin 2].
Mayer P, Hodgin L. Mayer P, et al. Zentralbl Veterinarmed A. 1987 Dec;34(10):755-65. Zentralbl Veterinarmed A. 1987. PMID: 3124399 German. No abstract available.
[Interleukin-2 and cancer immunotherapy].
Ogarkov VI, Dobkin AI, Ryzhova EV, Okulov VB, Kiselev OI. Ogarkov VI, et al. Vopr Onkol. 1989;35(2):141-50. Vopr Onkol. 1989. PMID: 2648678 Review. Russian. No abstract available.
[Interleukin 2].
Voĭtenok NN. Voĭtenok NN. Ter Arkh. 1988;60(5):42-6. Ter Arkh. 1988. PMID: 3051488 Review. Russian. No abstract available.
Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA. Rosenberg SA. Important Adv Oncol. 1986:55-91. Important Adv Oncol. 1986. PMID: 3330541 Review. No abstract available.

See all similar articles

Cited by

Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion.
Brunstein F, Hoving S, aan de Wiel-Ambagtsheer G, de Bruijn EA, Guetens G, Eggermont AM, ten Hagen TL. Brunstein F, et al. Cancer Immunol Immunother. 2007 Apr;56(4):573-80. doi: 10.1007/s00262-006-0206-y. Epub 2006 Aug 1. Cancer Immunol Immunother. 2007. PMID: 16896966 Free PMC article.
Immunological response as a source to variability in drug metabolism and transport.
Christensen H, Hermann M. Christensen H, et al. Front Pharmacol. 2012 Feb 10;3:8. doi: 10.3389/fphar.2012.00008. eCollection 2012. Front Pharmacol. 2012. PMID: 22363283 Free PMC article.
Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.
Bergers JJ, Den Otter W, Dullens HF, Kerkvliet CT, Crommelin DJ. Bergers JJ, et al. Pharm Res. 1993 Dec;10(12):1715-21. doi: 10.1023/a:1018913912580. Pharm Res. 1993. PMID: 8302756
Engineering approaches for innate immune-mediated tumor microenvironment remodeling.
Kane GI, Lusi CF, Brassil ML, Atukorale PU. Kane GI, et al. Immunooncol Technol. 2023 Oct 6;21:100406. doi: 10.1016/j.iotech.2023.100406. eCollection 2024 Mar. Immunooncol Technol. 2023. PMID: 38213392 Free PMC article. Review.
CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.
Lee JI, Zhang L, Men AY, Kenna LA, Huang SM. Lee JI, et al. Clin Pharmacokinet. 2010 May;49(5):295-310. doi: 10.2165/11319980-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20384392 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions